Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors – Cancer Therapy Advisor
Cancer Therapy Advisor |
Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors
Cancer Therapy Advisor So they invented a new investigational class of immunotherapies — “bifunctional antibody-ligand traps” (Y-traps) — to do just that. They engineered Y-traps composed of an antibody targeting either CTLA-4 or PD-L1, joined with a TGFβ receptor II … |
